(R)-4,5,6,7-Tetrahydro-N6-Propyl-2,6-Benzothiazolediamine Dihydrochloride

As a critical chiral impurity reference for the dopamine agonist pramipexole dihydrochloride monohydrate, (R)-4,5,6,7-Tetrahydro-N6-Propyl-2,6-Benzothiazolediamine Dihydrochloride (CAS 104632-28-2) is distributed in screw-cap amber vials containing 100 mg or 500 mg of a white to off-white crystalline powder. The lot-specific certificate of analysis issued under ISO 17034:2016 accreditation reports an enantiomeric excess of ≥ 99.5% by area normalization using a validated chiral HPLC method with a resolution factor (R_s) exceeding 2.0 between the (R)- and (S)-enantiomers. Achiral purity by HPLC (Ph.Eur. 2.2.29) is controlled to ≥ 98.5%, with any single unspecified impurity at < 0.15%. Loss on drying (USP <731>, 105 °C, 4 h) is held below 0.5% w/w, and residue on ignition (Ph.Eur. 2.4.14) is not more than 0.1%. The product is sealed under argon to suppress hygroscopic uptake and is stable for 36 months from the date of manufacture when stored between 2–8 °C.

What Chromatographic Parameters Govern Resolution on Amylose Tris(3,5-dimethylphenylcarbamate)?

Successful enantiomeric separation of the (R)-enantiomer from the (S)-pramipexole peak demands strict control of both mobile-phase composition and column temperature. On a 4.6 × 250 mm, 5 μm Chiralpak AD-H column (Daicel Corporation), baseline resolution (R_s ≥ 2.0) is achieved with a mobile phase of n-hexane/ethanol/diethylamine 80:20:0.1 (v/v/v) delivered at 1.0 mL/min and column temperature maintained at 25 ± 0.5 °C. The UV detector wavelength of 264 nm corresponds to the λ_max of the benzothiazole chromophore in its protonated form; molar absorptivity at this λ is 1.2 × 10⁴ L mol⁻¹ cm⁻¹ in 0.1 M HCl. A sample concentration of 0.5 mg/mL in mobile phase and an injection volume of 10 μL yield a signal-to-noise ratio exceeding 150:1 for the 0.05% limit of quantitation. Retention times typically span 12.3 min for the (S)-enantiomer and 15.1 min for the (R)-isomer under these conditions; response linearity (r² ≥ 0.999) is demonstrated across 0.05–2.0% of the nominal analyte concentration. Deviation of column temperature to 30 °C reduces the resolution to 1.5, while a 79:21 hexane/ethanol ratio broadens the later-eluting peak by 18% and increases tailing factor (USP <621>) to 1.9, rendering the method unsuitable for impurity profiling in the 0.05–0.3% range required by the European Pharmacopoeia monograph for pramipexole (limit of impurity B: ≤ 0.3%). Column lot-to-lot variability observed across 12 production batches of AD-H stationary phase necessitated pre-qualification with a system suitability mixture spiked to 0.1% of the (R)-enantiomer; lot acceptance criteria include a tailing factor for the (R)-peak of ≤ 1.3, resolution ≥ 2.0, and retention time RSD ≤ 2.0% over 6 consecutive injections.

When the (R)-Enantiomer Is Used as a Negative Control in Dopamine D2 Receptor Binding Assays

The (R)-configuration at the 6-position of the tetrahydrobenzothiazole ring abolishes the high-affinity interaction with D₂ and D₃ dopamine receptors observed for the (S)-enantiomer. In vitro radioligand displacement data with [³H]spiperone in transfected CHO cell membranes show a K_i for the (R)-enantiomer of > 1000 nM, compared to 0.5 ± 0.1 nM for pramipexole (S)-dihydrochloride (Kvernmo et al., Eur. J. Pharmacol. 2006). Consequently, the (R)-enantiomer is routinely employed as an enantiomeric purity spike in method validation protocols per ICH Q2(R1) and as a negative control in functional cAMP accumulation assays. When 1 μM of the (R)-enantiomer is co-incubated with 10 nM forskolin in HEK293 cells expressing human D_2S receptors, no statistically significant inhibition of cyclic AMP production is observed (mean ± SD inhibition 3.2 ± 1.8%, n = 6), confirming the stereospecificity of the pharmacological effect. This stark activity gap underpins the regulatory requirement that the (R)-impurity be controlled below 0.3% in the drug substance (Ph.Eur. monograph 01/2017:2416).

Long-term stability monitoring across 3 consecutive production lots stored at 25 °C/60% RH in original unopened argon-flushed vials confirmed no statistically significant degradation over 24 months; achiral purity remained at 98.8 ± 0.4%, and enantiomeric excess stayed above 99.4%. In contrast, when a 50 mg aliquot was exposed to ambient air at 55% RH at 22 °C, water uptake measured by Karl Fischer reached 1.8% w/w within 2 hours, causing localized deliquescence and a drop in titrimetric assay value by 3.5% relative to the anhydrous basis. The dihydrochloride salt reacts vigorously with strong oxidizing agents; treatment with 3% hydrogen peroxide at pH 7.4 generates a yellow chromophore absorbing at 380 nm within 30 minutes, indicating oxidative ring-opening of the thiazole moiety. Exposure to UV-A radiation (365 nm, 50 W/m²) for 2 hours results in a 6.8% increase in total impurities, primarily an oxidative desulfuration species at RRT 0.72. Compatibility studies demonstrate that dilution into Tris-HCl buffer (50 mM, pH 8.0) at 1 mg/mL leads to formation of an imine adduct via Schiff base condensation with the primary amine, evidenced by an HPLC peak eluting at relative retention time 1.3 and mass [M+H]⁺ m/z 354.2. Sample preparation for biological assays should therefore exclusively employ citrate or phosphate buffers at pH ≤ 7.0 and avoid primary amine-containing excipients. Shipment is conducted in validated insulated containers with frozen gel packs to maintain 2–8 °C for up to 96 hours; exposure to temperatures above 30 °C during transit induces a 0.2% enantiomeric excess loss per 24 hours, as measured by accelerated thermal cycling trials.

Crystallization Solvent and Polymorph Consistency Across Pilot Campaigns

The dihydrochloride salt used as the reference standard is recrystallized from a 2:1 (v/v) isopropanol/water mixture to yield Form A, the thermodynamically stable polymorph as confirmed by X-ray powder diffraction (XRPD) with characteristic peaks at 2θ values of 10.4°, 15.2°, and 22.7° (Cu Kα radiation). Differential scanning calorimetry (DSC) at a heating rate of 10 °C/min reveals a single endotherm at 224 ± 2 °C (onset, decomposition). Substitution of isopropanol by ethanol in the recrystallisation protocol (ethanol/water 1:1) produced a mixture of Form A and an unidentified polymorph displaying an additional DSC endotherm at 189 °C in 3 out of 8 pilot batches, rendering the product unsuitable for use as a certified reference material under ISO Guide 35:2017. Process validation on the 500 g scale using the isopropanol/water system across 5 consecutive GMP campaigns yielded uniform polymorphic composition and a batch-to-batch enantiomeric excess range of 99.6–99.9%, demonstrating that minor variations in cooling rate (0.5–2.0 °C/min) do not disturb the crystal form. Residual solvent levels of isopropanol, determined by headspace GC (Ph.Eur. 2.4.24), are controlled to < 0.5%.